Phase II-III Clinical Study of CSG452(RG7201) in Patients with Type 2 Diabetes. -Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Comparative Study in Monotherapy

Trial Profile

Phase II-III Clinical Study of CSG452(RG7201) in Patients with Type 2 Diabetes. -Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Comparative Study in Monotherapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 May 2016

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 27 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met, according to results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top